UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_____________________

FORM 10-Q

______________________


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2025


o			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 001-16133

______________________

DELCATH SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

______________________


Delaware			06-1245881
(State or other jurisdiction of incorporation or organization)			(I.R.S. Employer Identification No.)

566 Queensbury Avenue

Queensbury, NY 12804

(Address of principal executive offices)

(518) 743-8892

(Registrant’s telephone number, including area code)

______________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.01 par value per share

DCTH

The Nasdaq Capital Market

______________________

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of October 27, 2025, 35,313,718 shares of the Company’s common stock, $0.01 par value, were outstanding.

Table of Contents

DELCATH SYSTEMS, INC.

Table of Contents

		Page
PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements
	Unaudited Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024	3
	Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024	3
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income and Loss for the three and six months ended June 30, 2025 and 2024	4
	Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income and Loss for the three and nine months ended September 30, 2025 and 2024	4
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024	5
	Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2025 and 2024	5
	Unaudited Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024	7
	Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024	7
	Notes to the Unaudited Condensed Consolidated Financial Statements	89
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	2224
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	2629
Item 4.	Controls and Procedures	2629
PART II—OTHER INFORMATION		2830
Item 1.	Legal Proceedings	2830
Item 1A.	Risk Factors	2830
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	3032
Item 3.	Defaults Upon Senior Securities	3032
Item 4.	Mine Safety Disclosure	3032
Item 5.	Other Information	3133
Item 6.	Exhibits	3234
SIGNATURES		3435

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands, except share and per share data)

	June 30,2025		December 31,2024
	September 30,2025		December 31,2024
Assets
Current assets
Cash and cash equivalents	$	3441,~~421~~813	$	32,412
Short-term investments	4647,~~584~~099		20,821
Accounts receivable	1513,~~836~~751		10,890
Inventories	10,~~523~~745		6,933
Prepaid expenses and other current assets	67,~~118~~207		2,704
Total current assets	~~113~~120,~~482~~615		73,760
Property, plant and equipment, net	2,~~401~~715		1,790
Right-of-use assets	~~993~~965		1,039
Total assets	$	~~116~~124,~~876~~295	$	76,589
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	42,~~716~~133	$	961
Accrued expenses	5,~~603~~768		5,078
Lease liabilities, current	~~116~~110		105
Total current liabilities	108,~~435~~011		6,144
Lease Liabilities, non-current	877		933
Lease liabilities, non-current	855		933
Other liabilities, non-current	~~578~~582		766
Total liabilities	$	119,~~890~~448	$	7,843
Commitments and contingencies (see Note 12)
Stockholders’ equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 14,192 and 14,192 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	—		—
Preferred stock, $0.01 par value; 10,000,000 shares authorized; 14,192 and 14,192 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	—		—
Common stock, $0.01 par value; 80,000,000 shares authorized; 34,955,974 shares and 33,061,002 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively	350		331
Common stock, $0.01 par value; 80,000,000 shares authorized; 35,308,939 shares and 33,061,002 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	353		331
Additional paid-in capital	~~631~~640,~~826~~571		599,881
Accumulated deficit	(~~527~~526,~~782~~952)		(531,548)
Accumulated other comprehensive income	~~592~~875		82
Total stockholders’ equity	~~104~~114,~~986~~847		68,746
Total liabilities and stockholders’ equity	$	~~116~~124,~~876~~295	$	76,589

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Operations and Comprehensive Income and Loss

(Unaudited)

(in thousands, except share and per share data)

Three months ended June 30,

Six months ended June 30,

Three months ended September 30,

Nine months ended September 30,

2025

2024

2025

2024

Product revenue

2420,~~156~~563

711,~~766~~200

4364,~~940~~503

1022,~~905~~105

Cost of goods sold

(32,~~318~~624)

(1,~~519~~640)

(68,~~163~~787)

(24,~~422~~062)

Gross profit

2017,~~838~~939

69,~~247~~560

3755,~~777~~716

818,~~483~~043

Operating expenses:

Research and development expenses

67,~~882~~986

3,~~394~~866

1119,~~889~~875

710,~~094~~960

Selling, general and administrative expenses

1110,~~366~~341

6,~~765~~953

2232,~~656~~997

1522,~~579~~532

Total operating expenses

18,~~248~~327

10,~~159~~819

3452,~~545~~872

2233,~~673~~492

Operating income (loss)

~~2,590~~(388)

(31,~~912~~259)

32,~~232~~844

(1415,~~190~~449)

Change in fair value of warrant liability

—

(92,~~755)~~975

—

(107,~~367~~392)

Interest income (expense), net

~~649~~796

~~(84)~~113

12,~~267~~063

(~~283~~170)

Other income (expense)

(3433)

1035

(3063)

~~(12)~~23

Income (loss) before income taxes

~~3,205~~375

~~(13~~1,~~741)~~864

4,~~469~~844

(2422,~~852~~988)

Income tax expense

508

—

703

—

Income tax (benefit) expense

(455)

—

248

—

Net income (loss)

~~2,697~~830

~~(13~~1,~~741)~~864

34,~~766~~596

(2422,~~852~~988)

Other comprehensive income (loss):

Unrealized gain on investments adjustments

57296

(~~141~~14)

~~296~~592

(~~133~~147)

Foreign currency translation adjustments

~~154~~(13)

~~(8)~~17

~~214~~201

623

Total comprehensive income (loss)

21,~~908~~113

~~(13~~1,~~890)~~867

45,~~276~~389

(2423,~~979~~112)

Common share data:

Basic income (loss) per common share

0.0802

(0.~~48)~~06

0.1113

(0.9384)

Weighted average number of basic shares outstanding

3536,~~786~~383,~~813~~277

28,~~364~~738,~~731~~307

35,~~217~~610,~~887~~619

2627,~~625~~335,~~955~~212

Diluted income (loss) per common share

0.0702

(0.~~48)~~06

0.0912

(0.9384)

Weighted average number of dilutive shares outstanding

40,~~262~~056,~~764~~814

2832,~~364~~345,~~731~~672

39,~~890~~949,~~102~~941

2627,~~625~~335,~~955~~212

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(in thousands, except share data)

	Preferred Stock$0.01 Par Value			Common Stock$0.01 Par Value			AdditionalPaidin Capital		AccumulatedDeficit		AccumulatedOtherComprehensiveIncome		Total
	No. ofShares	Amount		No. ofShares	Amount
Balance at January 1, 2025	14,192	$	—	33,061,002	$	331	$	599,881	$	(531,548)	$	82	$	68,746
Compensation expense for issuance of stock options	—	—		—	—		6,813		—		—		6,813
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		50		—		—		50
Issuance of common stock with the Employee Stock Purchase Plan	—	—		35,513	—		238		—		—		238
Warrant Exercise - Series F	—	—		238,500	2		2,383		—		—		2,385
Stock Option Exercise	—	—		101,597	1		629		—		—		630
Net income	—	—		—	—		—		1,069		—		1,069
Unrealized gain on investment adjustments	—	—		—	—		—		—		239		239
Foreign currency translation adjustments	—	—		—	—		—		—		60		60
Balance at March 31, 2025	14,192	$	—	33,436,612	$	334	$	609,994	$	(530,479)	$	381	$	80,230
Compensation expense for issuance of stock options	—	—		—	—		7,159		—		—		7,159
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		50		—		—		50
Warrant Exercise - Series F	—	—		1,377,275	14		13,759		—		—		13,773
Stock Option Exercise	—	—		142,087	2		864		—		—		866
Net income	—	—		—	—		—		2,697		—		2,697
Unrealized gain on investment adjustments	—	—		—	—		—		—		57		57
Foreign currency translation adjustments	—	—		—	—		—		—		154		154
Balance at June 30, 2025	14,192	—$	—	34,955,974	~~350~~$	350	~~631,826~~$	631,826	~~(527,782)~~$	(527,782)	~~592~~$	592	~~104,986~~$	104,986
Compensation expense for issuance of stock options	—	—		—	—		5,567		—		—		5,567
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		81		—		—		81
Issuance of common stock with the Employee Stock Purchase Plan	—	—		22,858	—		243		—		—		243
Stock Option Exercise	—	—		330,107	3		2,854		—		—		2,857
Net income	—	—		—	—		—		830		—		830
Unrealized gain on investment adjustments	—	—		—	—		—		—		296		296
Foreign currency translation adjustments	—	—		—	—		—		—		(13)		(13)
Balance at September 30, 2025	14,192	$	—	35,308,939	$	353	$	640,571	$	(526,952)	$	875	$	114,847

Table of Contents

	Preferred Stock$0.01 Par Value			Common Stock$0.01 Par Value			AdditionalPaidin Capital		AccumulatedDeficit		AccumulatedOtherComprehensiveIncome (Loss)		Total
	No. ofShares	Amount		No. ofShares	Amount
Balance at January 1, 2024	24,819	$	—	22,761,554	$	228	$	520,576	$	(505,162)	$	135	$	15,777
Compensation expense for issuance of stock options	—	—		—	—		2,895		—		—		2,895
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		50		—		—		50
Private placement -issuance of common shares, net of expenses	—	—		876,627	8		6,904		—		—		6,912
Issuance of common stock with the Employee Stock Purchase Plan	—	—		21,140	—		74		—		—		74
Conversion - F-3 Preferred to Common	(8,010)	—		1,779,998	18		(17)		—		—		1
Net loss	—	$	—	—	$	—	$	—	$	(11,111)	$	—	$	(11,111)
Unrealized gain on investments	—	—		—	—		—		—		8		8
Foreign currency translation adjustments	—	—		—	—		—		—		14		14
Balance at March 31, 2024	16,809	—$	—	25,439,319	~~254~~$	254	~~530,482~~$	530,482	~~(516,273)~~$	(516,273)	~~157~~$	157	~~14,620~~$	14,620
Compensation expense for issuance of stock options	—	—		—	—		3,021		—		—		3,021
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		48		—		—		48
Prior quarter private placement - expenses	—	—		—	—		(141)		—		—		(141)
Warrant exercise and conversion - F-4 Preferred to Common	—	—		41,666	—		355		—		—		355
Conversion - F-3 Preferred to Common	(3,010)	—		668,888	7		(7)		—		—		—
Conversion - F-2 Preferred to Common	(1,457)	—		441,514	4		(4)		—		—		—
Pre-funded warrant exercise	—	—		1,307,706	13		(3)		—		—		10
Stock option exercise	—	—		32,300	1		168		—		—		169
Net loss	—	—		—	—		—		(13,741)		—		(13,741)
Unrealized loss on investments	—	—		—	—		—		—		(141)		(141)
Foreign currency translation adjustments	—	—		—	—		—		—		(8)		(8)
Balance at June 30, 2024	12,342	—$	—	27,931,393	~~279~~$	279	~~533,919~~$	533,919	~~(530,014)~~$	(530,014)	8$	8	~~4,192~~$	4,192
Compensation expense for issuance of stock options	—	—		—	—		2,092		—		—		2,092
Compensation expense for Employee Stock Purchase Plan	—	—		—	—		49		—		—		49
Issuance of common stock with the Employee Stock Purchase Plan	—	—		50,418	1		174		—		—		175
Stock option exercise	—	—		37,788	—		196		—		—		196
Net income	—	—		—	—		—		1,864		—		1,864
Unrealized loss on investments	—	—		—	—		—		—		(14)		(14)
Foreign currency translation adjustments	—	—		—	—		—		—		17		17
Balance at September 30, 2024	12,342	$	—	28,019,599	$	280	$	536,430	$	(528,150)	$	11	$	8,571

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

	Six months ended June 30,
	Nine months ended September 30,
	2025		2024
Cash flows from operating activities:
Net income (loss)	$	34,~~766~~596	$	(2422,~~852~~988)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock option compensation expense	1419,~~072~~720		68,~~014~~155
Depreciation expense	94158		6296
Warrant liability fair value adjustment	—		107,~~367~~392
Amortization of Right-of-Use Asset	5482		3764
Amortization of debt discount	—		~~447~~460
Interest expense accrued related to convertible notes	—		80120
Amortization of premiums and discounts on marketable securities	(~~765~~1,238)		(~~379~~450)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(3,~~091~~919)		(~~488~~353)
Accounts receivable	(42,~~946~~861)		(36,~~485~~695)
Inventory	(3,~~590~~812)		(23,~~994~~320)
Accounts payable and accrued expenses	41,~~137~~800		~~1,339~~120
Other liabilities, non-current	(~~235~~258)		(~~183~~276)
Net cash provided by (used in) operating activities	914,~~496~~268		(1417,~~035~~675)
Cash flows from investing activities:
Purchase of investment	(5161,~~152~~432)		(2031,~~482~~767)
Maturities of investments	2636,~~127~~400		3546,~~540~~344
Purchase of property, plant and equipment	(~~538~~997)		(~~114~~330)
Net cash (used in) provided by investing activities	(2526,~~563~~029)		14,~~944~~247
Cash flows from financing activities:
Net proceeds from private placement	—		6,771
Proceeds from the issuance of common stock relating to the employee stock purchase plan	~~238~~481		75250
Repayment of debt	—		(68,~~107~~610)
Proceeds from exercise of warrants	16,158		259
Proceeds from exercise of stock options	14,~~496~~353		~~169~~355
Net cash provided by financing activities	17,892		1,167
Net cash provided by (used in) financing activities	20,992		(975)
Foreign currency effects on cash	~~184~~170		1022
Net increase in total cash	2,009		2,086
Net increase (decrease) in total cash	9,401		(4,381)
Total Cash, Cash Equivalents and Restricted Cash:
Beginning of period	32,412		12,696
End of period	$	3441,~~421~~813	$	148,~~782~~315
Cash and Cash Equivalents consisted of the following:
Cash and Cash Equivalents	$	3441,~~409~~801	$	148,~~782~~315
Restricted Cash	12		—
Total	$	3441,~~421~~813	$	148,~~782~~315

	Six months ended June 30,
	2025		2024
Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest expense	$	—	$	375
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Right of use assets obtained in exchange for lease obligations	$	—	$	1,029

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

Table of Contents


	Nine months ended September 30,
	2025		2024
Supplemental Disclosure of Cash Flow Information:
Cash paid during the periods for:
Interest paid	$	—	$	389
Taxes paid	$	1,317	$	—
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Right of use assets obtained in exchange for lease obligations	$	—	$	1,029

See accompanying Notes to Unaudited Condensed Consolidated Financial Statements.

Table of Contents

DELCATH SYSTEMS, INC.

Notes to the Unaudited Condensed Consolidated Financial Statements

(amounts in thousands, except share and per share amounts)

(1) General

The unaudited interim condensed consolidated financial statements of Delcath Systems, Inc. (“Delcath” or the “Company”) as of and for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024 should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025 and may also be found on the Company’s website (www.delcath.com). In these notes to the interim condensed consolidated financial statements the terms “us”, “we” or “our” refer to Delcath and its consolidated subsidiaries.

Description of Business

The Company is an interventional oncology company focused on the treatment of primary and metastatic cancers to the liver. The Company’s lead product, the HEPZATOTM KIT (melphalan for Injection/Hepatic Delivery System) a drug/device combination product (“HEPZATO” or “HEPZATO KIT”), was approved by the US Food and Drug Administration (the “FDA”) on August 14, 2023, indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection, or radiation. The first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma (“mUM”) occurred in January 2024.

In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted Delcath six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).

The Company has sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and it intends to manage supply chain risk through stockpiled inventory and, where commercially reasonable, contracting with multiple suppliers for critical components.

In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (“CHEMOSAT”), where it has been used at major medical centers to treat a wide range of cancers in the liver. On February 28, 2022, CHEMOSAT received Medical Device Regulation (“MDR”) certification under the European Medical Devices Regulation (EU) 2017/745, which may be considered by jurisdictions when evaluating reimbursement. In June 2025, CHEMOSAT was approved for reimbursement for two years in the Vastra Gotaland Region in Sweden.

ToOn ~~support~~October 18, 2025, the ~~New~~Company ~~Drug~~announced ~~Application~~the ~~for~~results ~~HEPZATO~~of the ~~Company~~investigator-initiated ~~conducted~~CHOPIN clinical trial. The randomized Phase 2 trial was designed to compare the ~~FOCUS~~safety, ~~Clinical~~tolerability, ~~Trial~~and ~~for~~efficacy ~~Patients~~of CHEMOSAT with ~~metastatic~~melphalan ~~hepatic~~for ~~dominant~~percutaneous ~~Uveal~~hepatic ~~Melanoma~~perfusion (PHP) when used alone versus when combined with the ~~“FOCUS~~systemic ~~Trial”~~immune checkpoint inhibitors (ICI), aipilimumab ~~global~~and ~~registration~~nivolumab. ~~clinical~~Ipilimumab ~~trial~~and ~~that~~nivolumab ~~investigated~~are ~~objective~~approved ~~response~~by ~~rate~~the inFDA and European Union for the treatment of unresectable metastatic melanoma. The CHOPIN trial included 76 patients randomized 1:1 to receive two PHP treatments alone at weeks one and seven (PHP group) or four cycles of ICI every three weeks over approximately nine weeks with ~~mUM.~~two OnPHP ~~May~~treatments 6,at ~~2024,~~weeks ~~the~~one ~~Company~~and ~~announced~~seven ~~the~~(combination ~~publication~~group). The primary study endpoint of ~~results~~one-year ~~from~~progression-free ~~the~~survival ~~pivotal~~rate ~~FOCUS~~was ~~Trial~~met with 54.7% in the ~~journal~~combination ~~Annals~~group ofversus ~~Surgical~~15.8% ~~Oncology~~in the PHP group. InThe ~~addition,~~secondary onendpoints ~~April~~included 9Safety, ~~2025,~~Overall ~~the~~Survival ~~Company~~(“OS”), ~~announced~~Progression ~~the~~Free ~~publication~~Survival of(“PFS”) aand ~~comparative~~Overall ~~analysis~~Response ofRate ~~the~~(“ORR”). ~~randomized~~The ~~portion~~combination ofgroup ~~the~~saw ~~FOCUS~~an ~~Trial~~increase in ~~the~~median ~~Annals~~OS of ~~Surgical~~23.1 ~~Oncology~~months versus 19.6 ~~Currently,~~months ~~the~~(HR ~~Company’s~~= ~~clinical~~0.39; ~~development~~p ~~program~~= is0.006), ~~seeking~~median toPFS ~~generate~~12.8 ~~clinical~~months ~~data~~versus ~~for~~8.3 ~~CHEMOSAT~~months (HR = 0.34; p<0.001) and ~~HEPZATO~~ORR ~~either~~of as76.3% ~~monotherapy~~in the combination group versus 39.5% (p<0.001). Grade 3 or higher treatment-related adverse events were more frequent in the combination ~~with~~group ~~immunotherapy~~(81.6% ~~The~~versus ~~Company~~40.5%, ~~expects~~P<0.001), ~~that~~but ~~this~~most ~~will~~were ~~support~~manageable ~~increased~~with ~~clinical~~standard ~~adoption~~care. ofOverall, ~~and~~the ~~reimbursement~~combination ~~for~~treatment ~~CHEMOSAT~~was inwell ~~Europe~~tolerated, with types, rates and tofrequencies ~~support~~of ~~reimbursement~~adverse inevents ~~various~~consistent ~~jurisdictions,~~with ~~including~~individual ~~the~~use ~~United~~of ~~States~~PHP and checkpoint inhibitors. No new safety signals were identified.

InTo ~~addition~~support tothe ~~HEPZATO’s~~New ~~use~~Drug toApplication ~~treat~~for ~~mUM,~~HEPZATO the Company ~~believes~~conducted ~~that~~the ~~HEPZATO~~FOCUS ~~has~~Clinical ~~the~~Trial ~~potential~~for toPatients ~~treat~~with ~~other~~metastatic ~~cancers~~hepatic indominant Uveal Melanoma (the ~~liver~~“FOCUS Trial”), ~~such~~a asglobal ~~metastatic~~registration ~~colorectal~~clinical ~~cancer,~~trial ~~metastatic~~that ~~breast~~investigated ~~cancer,~~objective ~~metastatic~~response ~~neuroendocrine~~rate ~~tumors,~~in ~~and~~patients ~~intrahepatic~~with ~~cholangiocarcinoma~~mUM. ~~The~~On May 6, 2024, the Company ~~believes~~announced ~~that~~the ~~those~~publication ~~and~~of ~~similar~~results ~~disease~~from ~~states~~the ~~are~~pivotal ~~areas~~FOCUS Trial in the journal Annals of ~~unmet~~Surgical ~~medical~~Oncology. ~~needs~~In ~~that~~addition, ~~represent~~on ~~significant~~April ~~market~~9, ~~opportunities.~~2025, the Company

Table of Contents

~~will~~announced ~~take~~the ~~place~~publication atof ~~more~~a ~~than~~comparative 20analysis ~~sites~~of ~~across~~the randomized portion of the ~~United~~FOCUS ~~States~~Trial ~~and~~in ~~Europe~~the Annals of Surgical Oncology. Currently, ~~with~~the ~~patient~~Company’s ~~enrollment~~clinical ~~expected~~development toprogram ~~begin~~is inseeking ~~the~~to ~~second~~generate ~~half~~clinical ofdata ~~2025.~~for InCHEMOSAT ~~July~~and ~~2025,~~HEPZATO ~~the~~either ~~Company~~as ~~received~~monotherapy ~~authorization~~or ~~from~~in ~~the~~combination ~~European~~with ~~Union~~immunotherapy. ~~and~~The ~~United~~Company ~~Kingdom~~expects ~~regulatory~~that ~~authorities~~this ~~for~~will ~~the~~support increased clinical ~~study~~adoption of ~~Melphalan~~and reimbursement for ~~Injection/Hepatic~~CHEMOSAT ~~Delivery~~in ~~System~~Europe, inand ~~patients~~to ~~with~~support ~~refractory~~reimbursement ~~metastatic~~in ~~colorectal~~various ~~cancer~~jurisdictions, ~~with~~including ~~liver~~the ~~dominant~~United ~~disease~~States.

OnIn ~~April~~addition ~~28,~~to ~~2025,~~HEPZATO’s ~~the~~use ~~Company~~to ~~announced~~treat ~~the~~mUM, ~~clearance by~~ the ~~FDA~~Company ofbelieves ~~its~~that ~~IND~~HEPZATO ~~application~~has ~~for~~ the ~~Phase~~potential 2to ~~clinical~~treat ~~trial~~other ofcancers ~~HEPZATO~~ in ~~liver-dominant metastatic breast cancer. The Phase 2 trial will evaluate~~ the ~~safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with~~ liver~~-dominant~~, ~~HER2-negative~~such ~~mBC~~as ~~following~~metastatic ~~the~~colorectal ~~failure~~cancer, ofmetastatic ~~previous~~breast ~~treatments.~~cancer, ~~The~~metastatic ~~SOC~~neuroendocrine ~~options will be the physician’s choice of eribulin~~tumors, ~~vinorelbine~~and orintrahepatic ~~capecitabine~~cholangiocarcinoma. ~~We expect approximately 90 patients will be enrolled in this randomized, controlled trial.~~ The ~~trial~~Company ~~will~~believes ~~take~~that ~~place~~those ~~at more than 20 sites across the United States~~ and ~~Europe,~~similar ~~with~~disease ~~patient~~states ~~enrollment~~are ~~expected~~areas toof ~~begin~~unmet inmedical ~~the~~needs ~~fourth~~that ~~quarter~~represent ofsignificant ~~2025.~~market opportunities.

The Company’s investigational new drug application (“IND”) for a Phase 2 clinical trial evaluating HEPZATO in combination with standard of care (“SOC”) for liver-dominant metastatic colorectal cancer was cleared by the FDA in December 2024. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. Approximately 90 patients will be enrolled in this randomized, controlled trial. Patient enrollment began during the third quarter of 2025, with the study expected to take place at more than 20 sites across the United States and Europe. In July 2025, the Company received authorization from the European Union and United Kingdom regulatory authorities for the clinical study of Melphalan for Injection/Hepatic Delivery System in patients with refractory metastatic colorectal cancer with liver dominant disease.

On April 28, 2025, the Company announced the clearance by the FDA of its IND application for the Phase 2 clinical trial of HEPZATO in liver-dominant metastatic breast cancer. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC following the failure of previous treatments. The SOC options will be the physician’s choice of eribulin, vinorelbine or capecitabine. We expect approximately 90 patients will be enrolled in this randomized, controlled trial. The trial will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the first quarter of 2026.

Risks and Uncertainties

As detailed in the Company’s 2024 Annual Report filed on Form 10-K, the Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company’s ability to obtain regulatory approval of its such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.

In addition, high rates of inflation have resulted in the United States Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners’ ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company’s business and financial condition, including the Company’s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company’s ability to pursue its business strategy.

Factors such as geopolitical events, global health outbreaks, adverse weather events, labor or raw material shortages, imposition of tariffs or trade restrictions and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages, including increasing the cost of ongoing clinical trials. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation.

The United States has announced a broad range of tariffs on goods imported into the United States, many of which were then paused. The majority of the Company’s sales are domestic, and while the Company sources certain components outside of the United States, the costs associated with imported materials needed for its operations is a modest portion of our overall manufacturing costs. The Company will continue to monitor the implementation and effect of these and other proposed tariffs.

~~Liquidity~~ 10

The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

On June 30, 2025, the Company had cash and cash equivalents totaling $34.4 million and short-term investments totaling $46.6 million, as compared to cash and cash equivalents totaling $32.4 million and short-term investments totaling $20.8 million at December 31, 2024. During the six months ended June 30, 2025, cash provided by operating activities was $9.5 million.

The Company believes that the current cash on hand, cash equivalents, investments and net cash provided by operating activities will be sufficient to support current operations through at least 12 months from the issuance of these condensed consolidated financial statements. Actual future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and

Table of Contents

~~enforcing~~Liquidity ~~intellectual property rights; the resolution of any disputes with third parties; and the effect of competing technological and market developments.~~

The ~~Company’s~~accompanying ~~capital~~condensed ~~commitments~~consolidated ~~over~~financial ~~the~~statements ~~next~~have ~~twelve~~been ~~months~~prepared ~~include~~on ~~$10.4~~a ~~million~~basis towhich ~~satisfy~~assumes ~~accounts~~that ~~payable,~~the ~~accrued~~Company ~~expenses,~~will ~~current~~continue ~~lease~~as ~~liabilities~~a ~~and~~going ~~current~~concern ~~medac~~and ~~settlement.~~contemplates ~~Additional capital commitments beyond~~ the ~~next~~realization ~~twelve~~of ~~months~~assets ~~include~~and ~~(a)~~the ~~$1.2~~satisfaction ~~million~~ of ~~lease~~ liabilities; and ~~(b)~~commitments ~~$0.6~~in ~~million~~the ~~for~~normal ~~settlement~~course of ~~litigation with medac~~business. ~~For more information on the medac settlement, see Note 12 - “Commitments and Contingencies - medac Matter”.~~

On September 30, 2025, the Company had cash and cash equivalents totaling $41.8 million and short-term investments totaling $47.1 million.

Basis of Presentation

These interim condensed consolidated financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and with the SEC’s instructions to Form 10-Q and Article 10 of Regulation S-X. They include the accounts of all wholly owned subsidiaries and all significant inter-company accounts and transactions have been eliminated in consolidation.

The preparation of interim condensed consolidated financial statements requires management to make assumptions and estimates that impact the amounts reported. These interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the Company’s results of operations, financial position and cash flows for the interim periods ended ~~June~~September 30, 2025 and 2024; however, certain information and footnote disclosures normally included in our audited consolidated financial statements which were included in the Annual Report have been condensed or omitted as permitted by GAAP. It is important to note that the Company’s results of operations and cash flows for interim periods are not necessarily indicative of the results of operations and cash flows to be expected for a full fiscal year or any interim period.

Significant Accounting Policies

~~There~~Management has performed its quarterly evaluation of policies and there have been no material changes to our significant accounting policies as set forth in Note 3 Summary of Significant Accounting Policies to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Recent Accounting Pronouncements

No new accounting standards were adopted during the ~~six~~nine months ended ~~June~~September 30, 2025. The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

ASU 2024-03, Disaggregation of Income Statement Expenses

In November 2024, the Financial Accounting Standards Board (“FASB”) issued ASU 2024-03, Income Statement - Reporting Comprehensive Income (Topic 220): Expense Disaggregation Disclosures to improve the disclosures about a public entity’s expenses and provide more detailed information about the types of expenses in commonly presented expense captions such as inventory purchases, employee compensation, depreciation and intangible asset amortization. The disclosure requirements must be applied retrospectively to all prior periods presented in the financial statements. The effective date for the standard is for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the effects adoption of this guidance will have on the consolidated financial statements.

ASU 2023-09, Improvements to Income Tax Disclosures

On December 14, 2023, the FASB issued, ASU 2023-09, Improvements to Income Tax Disclosures, a final standard on improvements to income tax disclosures. The standard requires disaggregated information about a reporting entity’s

Table of Contents

effective tax rate reconciliation as well as information on income taxes paid. The standard applies to all entities subject to income taxes and is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. For public business entities (PBEs), the new requirements will be effective for annual periods beginning after December 15, 2024. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively. The Company is currently in the process of evaluating the effect of this guidance on its financial statements.

(2) Revenue

The Company recognizes product revenue from sales of HEPZATO in the United States and CHEMOSAT in certain European countries in accordance with the five-step model in Accounting Standards Codification (“ASC”) 606, Revenue Recognition: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation. Under this revenue standard, the Company recognizes revenue when its customer obtains control of the promised goods, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods.

HEPZATO

The Company ships and sells the HEPZATO KIT directly to hospitals and treating centers based on approved agreements. For certain customers, the inventory is considered on consignment in which the Company retains title to the product until the use of the HEPZATO KIT. For these sales, the Company recognizes HEPZATO revenue, based on contracted or published rates, upon completion of the procedure. There is no obligation for the hospitals or treating centers to use the consigned HEPZATO, and the Company has no contractual right to receive payment until the product is used in a procedure and transfer of control is completed. See Note 4 for further information regarding consignment inventory.

Hospitals and treating centers may also elect to purchase HEPZATO KITS prior to a procedure. For these sales, the purchasing hospital or treatment center obtains control of the product once it is delivered. In these instances, the Company recognizes the HEPZATO KIT revenue based on contracted rates stated in an approved contract or purchase order upon delivery to the customer. There are no contractual rights of returns, refunds or similar obligations.

On May 22, 2025, the Company announced a plan to enter into a National Drug Rebate Agreement (“NDRA”) with the Centers for Medicare and Medicaid Services (“CMS”), which also subjected the Company to entering into a Pharmaceutical Pricing Agreement (“PPA”) with the Public Health Service and a master agreement with the U.S. Department of Veterans Affairs (“VA”). Pursuant to the NDRA, the Company must pay mandated rebates to states for Medicaid usage. Under the PPA, beginning on July 1, 2025, the Company began selling HEPZATO to eligible covered entities at the statutory 340B price. The Company is also obligated to make any sales to the VA at the Federal Ceiling Price. The NDRA, the PPA, and the agreement with the VA requires the Company to calculate and submit additional pricing calculations and subject the Company to potential penalties for failing to make timely and/or accurate reports of the required values.

CHEMOSAT

CHEMOSAT is sold directly to hospitals in the European Union and United Kingdom based on contracted rates in an approved contract or sales order. The Company recognizes product revenue from sales of CHEMOSAT upon shipment.

Table of Contents

Revenue by product for the periods indicated were as follows:

Three Months Ended June 30,

Six Months Ended June 30,

Three Months Ended September 30,

Nine Months Ended September 30,

(In thousands)

2025

2024

2025

2024

CHEMOSAT

1,~~656~~310

1,~~196~~163

34,~~417~~727

23,~~327~~490

HEPZATO KIT

2219,~~500~~253

610,~~570~~037

4059,~~523~~776

818,~~578~~615

Total revenue

2420,~~156~~563

711,~~766~~200

4364,~~940~~503

1022,~~905~~105

Concentration of Credit Risk

Potential credit risk exposure for both the HEPZATO KIT and CHEMOSAT has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The loss percentage is calculated ~~through the use of current and historical economic and financial information. As of June 30, 2025, there were no estimated losses applied to the accounts receivables balance.~~

The Company’s total percentage of revenue and accounts receivable balances were comprised of the following concentrations from its largest customers, based on whose revenue and/or accounts receivable concentration is greater than 10% of total revenue or total accounts receivable in the periods disclosed below:12

For the six months ended and as of June 30, 2025	% of Revenue		% of Accounts Receivable
Customer 1	13.1	%	11.8	%
Customer 2	12.3	%	14.2	%
Customer 3	11.0	%	5.9	%

For the six months ended and as of June 30, 2024	% of Revenue		% of Accounts Receivable
Customer 1	51.7	%	34.3	%
Customer 2	23.5	%	29.4	%
Customer 3	11.7	%	4.9	%

On May 22, 2025, Delcath announced a plan to enter into the National Drug Rebate Agreement (“NDRA”) with the Centers for Medicare and Medicaid Services (“CMS”), which also subjected the Company to entering into a Pharmaceutical Pricing Agreement (“PPA”) with the Public Health Service and a master agreement with the U.S. Department of Veterans Affairs (“VA”). Pursuant to the NDRA, the Company must pay mandated rebates to states for Medicaid usage. Under the PPA, beginning on July 1, 2025, the Company began selling HEPZATO to eligible covered entities at the statutory 340B price. The Company is also obligated to make any sales to the VA at the Federal Ceiling Price. The NDRA, the PPA, and the agreement with the VA requires the Company to calculate and submit additional pricing calculations and subject the Company to potential penalties for failing to make timely and/or accurate reports of the required values.

Table of Contents

through the use of current and historical economic and financial information. As of September 30, 2025, there were no estimated losses applied to the accounts receivables balance.


For the nine months ended and as of September 30, 2025	% of Revenue		% of Accounts Receivable
Customer 1	13.9	%	15.0	%
Customer 2	11.3	%	16.4	%
Customer 3	10.1	%	4.1	%
Customer 4	5.8	%	10.9	%


For the nine months ended and as of September 30, 2024	% of Revenue		% of Accounts Receivable
Customer 1	28.1	%	21.0	%
Customer 2	19.0	%	23.7	%
Customer 3	12.4	%	13.2	%

(3) Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments - Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets.

The following table summarizes the gross unrealized gains on the Company’s marketable securities as of ~~June~~September 30, 2025:

June 30, 2025

September 30, 2025

Gross Unrealized

(In thousands)

Amortized Cost

Gains

Estimated Fair Value

U.S. government agency bonds

46,~~153~~372

~~431~~727

4647,~~584~~099

Short-term investments

4647,~~584~~099

As of ~~June~~September 30, 2025, there was $0.47 million of interest receivable related to the outstanding debt securities held by the Company.

The following table summarizes the gross unrealized gains on the Company’s marketable securities as of December 31, 2024:


	December 31, 2024
			Gross Unrealized
(in thousands)	Amortized Cost		Gains		Estimated Fair Value
U.S. government agency bonds	$	20,686	$	135	$	20,821
Short-term investments					$	20,821

As of December 31, 2024, there was $0.1 million of interest receivable related to the outstanding debt securities held by the Company.

~~(4) Inventory~~13

(In thousands)	June 30,2025		December 31,2024
Raw materials	$	7,227	$	3,849
Work-in-process	2,339		2,260
Finished goods	957		824
Total inventory	$	10,523	$	6,933

The Company has consignment agreements with approved hospitals and treatment centers. As of June 30, 2025, there was approximately $0.6 million in finished goods held at hospitals and treatment centers.

Table of Contents

(4) Inventory

Inventory consists of the following:


(In thousands)	September 30, 2025		December 31, 2024
Raw materials	$	7,041	$	3,849
Work-in-process	2,710		2,260
Finished goods	994		824
Total inventory	$	10,745	$	6,933

The Company has consignment agreements with approved hospitals and treatment centers. As of September 30, 2025, there was approximately $0.6 million in finished goods held at hospitals and treatment centers.

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:

(In thousands)	~~June~~September 30,2025		December 31,2024
Clinical trial expenses	$	2,405	$	222
Insurance premiums	~~188~~180		161
Professional services	1,~~249~~057		762
Interest receivable	~~448~~709		125
Licenses	~~498~~682		990
Software	~~404~~670		164
Taxes	~~489~~1,104		45
Prepayments on project initiatives	80		—
Other	400		235
Other	357		235
Total prepaid expenses and other current assets	$	7,207	$	2,704
Total prepaid expenses and other current assets	$	6,118	$	2,704

(6) Property, Plant, and Equipment

Property, plant, and equipment consist of the following:

(In thousands)	~~June~~September 30,2025		December 31, 2024		Estimated Useful Life
Buildings and land	$	1,318	$	1,318	30 years - Buildings
Enterprise hardware and software	1,~~818~~819		1,811		3 years
Leaseholds	1,648		1,585		Lesser of lease term or estimated useful life
Equipment	2,~~209~~512		1,671		7 years
Furniture	251		232		5 years
Equipment in process	~~260~~335		127
Property, plant and equipment, gross	7,~~504~~883		6,744
Accumulated depreciation	(5,~~103~~168)		(4,954)
Property, plant and equipment, net	$	2,~~401~~715	$	1,790

Depreciation expense for the three ~~and six~~ months ended ~~June~~September 30, 2025 and 2024 was less than $0.1 million for each period and depreciation expense for the nine months ended September 30, 2025 and 2024 was less than $0.2 million and $0.1 million, respectively.

~~(7) Accrued Expenses~~14

(In thousands)	June 30,2025		December 31,2024
Clinical expenses	$	1,095	$	615
Compensation, excluding taxes	2,891		3,471
ESPP withholding	255		240
Professional fees	305		57
Inventory	222		44
medac	224		208
Other	611		443
Total accrued expenses	$	5,603	$	5,078

Table of Contents

(7) Accrued Expenses

Accrued expenses consist of the following:


(In thousands)	September 30, 2025		December 31, 2024
Clinical expenses	$	1,176	$	615
Compensation, excluding taxes	3,433		3,471
ESPP withholding	202		240
Professional fees	251		57
Inventory	102		44
medac	225		208
Other	379		443
Total accrued expenses	$	5,768	$	5,078

(8) Leases

The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company leases its facilities under non-cancellable operating leases. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the ROU asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments.

For both the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024, the Company recognized ~~less~~approximately ~~than~~ $0.1 million of operating lease expense and less than $0.1 million was recorded for short-term leases.

In 2021, the Company entered into a sub-lease agreement (the “2021 Sub-Lease”) with its previous sub-lessee pursuant to which, effective August 2, 2021, the previous sub-lessee would become the lessee and the Company would then sublease its portion of the premises in Galway, Ireland from the previous sub-lessee. The Company’s annual rent expense under the 2021 Sub-Lease is less than $0.1 million for a term of 5 years.

On January 18, 2024, the Company entered into a lease agreement (the “Queensbury Lease”) to lease approximately 18,000 square feet of manufacturing and office space in Queensbury, New York. The initial term of the lease is five years with a right to extend the lease by an additional five years, exercisable under certain conditions set forth in the Queensbury Lease. The Company’s annual rent expense under the Queensbury Lease is less than $0.2 million for a term of 5 years.

The following table summarizes the Company’s operating leases as of September 30, 2025:

(In thousands)	U.S.			Ireland			Total
Operating cash flows for operating leases	$	(72108)		$	(22)		$	(94130)
Weighted average remaining lease term	8.63			10.18
Weighted average discount rate - operating leases	8		%	8		%

Table of Contents

Remaining maturities of the Company’s operating leases, excluding short-term leases, are as follows:

(In thousands)	U.S.		Ireland		Total
Year ended December 31, 2025	$	7236	$	2412	$	9648
Year ended December 31, 2026	144		27		171
Year ended December 31, 2027	148		—		148
Year ended December 31, 2028	152		—		152
Year ended December 31, 2029	157		—		157
Thereafter	643		—		643
Total	1,~~316~~280		5139		1,~~367~~319
Less present value discount	(~~372~~353)		(21)		(~~374~~354)
Operating lease liabilities included in the condensed consolidated balance sheets at June 30, 2025	$	944	$	49	$	993
Operating lease liabilities included in the condensed consolidated balance sheets at September 30, 2025	$	927	$	38	$	965

(9) Stockholders’ Equity

Public and Private Placements

June 2024 Shelf Registration Statement

On June 28, 2024, the Company filed a universal shelf registration statement on Form S-3 (the “June 2024 Shelf Registration Statement”) with the SEC, pursuant to which the Company may offer, issue and sell any combination of shares of the Company’s common stock, par value $0.01 per share, shares of the Company’s preferred stock, par value $0.01 per share, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, in one or more series, and units consisting of any combination of the other types of securities registered under such June 2024 Shelf Registration Statement in an aggregate amount of up to $150 million, in each case, to the public in one or more registered offerings. The June 2024 Shelf Registration Statement was declared effective on August 5, 2024.

Table of Contents

Authorized Shares

The Company is authorized to issue 80 million shares of common stock, $0.01 par value, and 10 million shares of preferred stock, $0.01 par value. As of ~~June~~September 30, 2025, the Company has designated the following preferred stock:

Designated Preferred Shares						~~June~~September 30, 2025
Series A						4,200
Series B						2,360
Series C						590
Series D						10,000
Series E						40,000
Series E-1						12,960
Series F-1						24,900
Series F-2						24,900
Series F-3						34,860
Series F-4						24,900
Total						179,670

Preferred Stock

As of ~~June~~September 30, 2025, there were an aggregate of 10,957 shares of Series E and Series E-1, 1,085 Series F-2 and 2,150 Series F-4 Convertible Preferred Stock outstanding, respectively.

Table of Contents

Subject to limitations set forth in the Beneficial Ownership Limitation, the shares of Series E and E-1 Preferred Stock are convertible into common stock at the option of the holder at the conversion price of $10.00 per share.

Subject to limitations set forth in the Certificate of Designation, the shares of Series F-2 and F-4 Preferred Stock are convertible into common stock at the option of the holder at the conversion price of $3.30 per share and $6.00 per share, respectively, rounded down to the nearest whole share, and in each case subject to the terms and limitations contained in the Certificate of Designation.

The outstanding Series F-2 and F-4 Preferred Stock are not mandatorily redeemable, redeemable at the holder’s election or contingently redeemable at the holder’s election (at this point, a Deemed Liquidation Event would potentially trigger pro rata liquidation payments to the preferred and common stockholders on a pro rata “as converted” basis). Accordingly, the Series F-2 and F-4 Preferred are classified as permanent equity.

Omnibus Equity Incentive Plan

On September 30, 2020, the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 Plan”) was adopted by the Company’s Board of Directors. On November 23, 2020, the Company’s stockholders approved the 2020 Plan. The 2020 Plan will continue in effect until the tenth anniversary of the date of its adoption by the Board or until earlier terminated by the Board. The 2020 Plan is administered by the Board of Directors or a committee designated by the Board of Directors. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed to be consistent with the purposes of the plan to Company employees, directors and consultants. As of ~~June~~September 30, 2025, there ~~are~~have been 9,325,000 shares of common stock reserved under the 2020 Plan, which includes the additional 2,200,000 shares approved by shareholders on May 15, 2025, of which 2,~~382~~457,~~636~~579 shares of common stock remained available to be issued as of September 30, 2025 under the 2020 Plan.

In addition to options granted from the 2020 Plan, the Company also grants employment inducement awards pursuant to Listing Rule 5635(c)(4) of the corporate governance rules of the Nasdaq Stock Market. The inducement grants are intended to provide incentive to certain individuals to enter into employment with the Company. Prior to December 5, 2023, the inducement awards were granted outside of the 2020 Plan, however they are governed in all respects as if they were issued under the 2020 Plan. These grants do not reduce the number of options available for issuance under the 2020 Plan.

15On December 5, 2023, the Company’s 2023 Inducement Plan (the “2023 Plan”) was adopted by the Company’s Board of Directors. The 2023 Plan is administered by a Compensation Committee of two or more Independent Directors appointed by the Board of Directors and is intended to provide for the grant of non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed appropriate to incentivize employment with the Company. Awards from the 2023 Plan can only be granted to individuals who have not previously worked for the Company or have not worked for the Company for a bona fide period of time. As of September 30, 2025, there have been 1,100,000 shares of common stock reserved under the 2023 Plan, of which 237,086 remain available to be granted.

Table of Contents

On December 5, 2023, the Company’s 2023 Inducement Plan (the “2023 Plan”) was adopted by the Company’s Board of Directors. The 2023 Plan is administered by a Compensation Committee of two or more Independent Directors appointed by the Board of Directors and is intended to provide for the grant of non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, as well as other stock-based awards or cash awards that are deemed appropriate to incentivize employment with the Company. Awards from the 2023 Plan can only be granted to individuals who have not previously worked for the Company or have not worked for the Company for a bona fide period of time. As of June 30, 2025, there have been 1,100,000 shares of common stock reserved under the 2023 Plan, of which 307,131 remain available to be granted.

Stock Options

The following tables include information for all options granted including inducement grants that are granted outside of the 2020 Plan.

The Company values stock options using the Black-Scholes option pricing model and used the following assumptions, on a weighted-average basis, during the reporting periods:

	Six Months Ended June 30,
	Nine Months Ended September 30,
	2025	2024
Expected terms (years)	5.7	5.56
Expected volatility	89.21%	114.30%
Risk-free interest rate	4.3230%	4.2220%
Expected dividends	0.00%	0.00%

~~The following is a summary of stock option activity for the six months ended June 30, 2025:~~ 17

	Number of Options	Weighted AverageExercise Price Per Share		Weighted AverageRemainingContractual Term(in years)	Aggregate IntrinsicValue(in thousands)
Outstanding at January 1, 2025	5,766,927	$	7.23	7.5	$	28,796
Granted	2,632,163	15.76		9.6
Exercised	(243,684)	6.14
Expired	(786)	16.25
Cancelled/Forfeited	(72,377)	9.88
Outstanding at June 30, 2025	8,082,243	$	10.01	7.9	$	35,672
Exercisable at June 30, 2025	4,242,694	$	8.57	6.7	$	22,968
Unvested at June 30, 2025	3,839,549	$	11.61	9.2	$	12,704

The weighted average grant-date fair value of stock options granted during the six months ended June 30, 2025 and 2024 was $11.82 and $4.09, respectively. The aggregate intrinsic value of stock options exercised was $2.2 million and $0.1 million for the six months ended June 30, 2025 and June 30, 2024, respectively. Total cash received as a result of stock option exercises was $1.5 million and $0.2 million for the six months ended June 30, 2025 and June 30, 2024, respectively.

	Three Months Ended June 30,				Six Months Ended June 30,
(In thousands)	2025		2024		2025		2024
Selling, general and administrative	$	4,718	$	1,930	$	9,247	$	3,971
Research and development	1,773		895		3,341		1,543
Cost of goods sold	718		244		1,484		500
Total	$	7,209	$	3,069	$	14,072	$	6,014

At June 30, 2025, there was $21.2 million of aggregate unrecognized compensation expense related to employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 1.04 years.

Table of Contents

The following is a summary of stock option activity for the nine months ended September 30, 2025:


	Number of Options	Weighted Average Exercise Price Per Share		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value (in thousands)
Outstanding at January 1, 2025	5,766,927	$	7.23	7.5	$	28,796
Granted	2,710,163	15.62		9.4
Exercised	(573,791)	7.59
Expired	(63,175)	12.83
Cancelled/Forfeited	(93,243)	10.33
Outstanding at September 30, 2025	7,746,881	$	10.06	8.0	$	20,184

Exercisable at September 30, 2025	4,365,983	$	8.64	7.2	$	13,690
Unvested at September 30, 2025	3,380,898	$	11.88	9.0	$	6,494

The weighted average grant-date fair value of stock options granted during the nine months ended September 30, 2025 and 2024 was $11.71 and $4.22, respectively. The aggregate intrinsic value of stock options exercised was $3.0 million and $0.2 million for the nine months ended September 30, 2025 and September 30, 2024, respectively. Total cash received as a result of stock option exercises was $4.4 million and $0.4 million for the nine months ended September 30, 2025 and September 30, 2024, respectively.

The following is a summary of share-based compensation expense in the statement of operations:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2025		2024		2025		2024
Selling, general and administrative	$	3,566	$	1,530	$	12,813	$	5,502
Research and development	1,551		411		4,892		1,954
Cost of goods sold	531		200		2,015		699
Total	$	5,648	$	2,141	$	19,720	$	8,155

At September 30, 2025, there was $16.1 million of aggregate unrecognized compensation expense related to employee and board stock option grants. The cost is expected to be recognized over a weighted average period of 0.94 years.

Table of Contents

Common Stock Warrants

The following is a summary of common stock warrant activity for the nine months ended September 30, 2025:

	Warrants	Weighted Average Exercise Price
Outstanding at January 1, 2025	3,193,275	$	5.80
Warrants issued	—	—
Warrants exercised	(1,615,775)	10.00
Warrants canceled	(236,125)	10.00
Outstanding and exercisable at June 30, 2025	1,341,375	$	0.01
Outstanding and exercisable at September 30, 2025	1,341,375	$	0.01

The following table presents information related to common stock warrants outstanding at September 30, 2025:


	Warrants Exercisable
Range of Exercise Prices	Outstanding Number of Warrants	Weighted Average Remaining Warrant Term (in years)
$0.01 (1)	1,341,375	n/a

(1) Pre-funded warrants with a $0.01 exercise price do not expire until exercised.

Employee Stock Purchase Plan

In August 2021, the Company’s Board of Directors, with shareholder approval in May 2022, adopted the Employee Stock Purchase Plan (the “ESPP”). The ESPP provides for a maximum of 560,295 shares of common stock to be purchased by participating employees, which includes an additional 300,000 shares approved by shareholders on May 15, 2025, of which ~~148~~171,~~506~~364 have been issued as of ~~June~~September 30, 2025 since the inception of the benefit in 2021. Employees who elect to participate in the ESPP will be able to purchase common stock at the lower of 85% of the fair market value of common stock on the first or last day of the applicable six-month offering period.

(10) Net Income (Loss) per Share

Basic net income or loss per share is determined by dividing net loss by the weighted average shares of common stock outstanding during the period, without consideration of potentially dilutive securities, except for those shares that are issuable for little or no cash consideration. Diluted net income or loss per share is determined by dividing net income or loss by diluted weighted average shares outstanding. Diluted weighted average shares reflects the dilutive effect, if any, of potentially dilutive common shares, such as stock options and warrants calculated using the treasury stock method. In periods with reported net operating losses, all common stock options, convertible preferred shares, and preferred and common warrants are generally deemed anti-dilutive such that basic net loss per share and diluted net loss per share are equal.

As of ~~June~~September 30, 2025 and 2024, the Company had 1,341,375 and 737,421 pre-funded warrants outstanding, respectively. The following table provides a reconciliation of the weighted average shares outstanding calculation for the three and ~~six~~nine months ended ~~June~~September 30, 2025 and 2024:

Weighted average number of basic shares outstanding

Three months ended June 30,

Six months ended June 30,

Three months ended September 30,

Nine months ended September 30,

2025

2024

2025

2024

Weighted average shares issued

3435,~~445~~041,~~438~~902

2728,~~317~~000,~~256~~886

3334,~~876~~269,~~512~~244

2526,~~511~~347,~~315~~229

Weighted average pre-funded warrants

1,341,375

1737,~~047,475~~421

1,341,375

1987,~~114,640~~983

Weighted average shares outstanding

3536,~~786~~383,~~813~~277

28,~~364~~738,~~731~~307

35,~~217~~610,~~887~~619

2627,~~625~~335,~~955~~212

1719

Table of Contents

Weighted average number of diluted shares outstanding

Three months ended June 30,

Six months ended June 30,

Three months ended September 30,

Nine months ended September 30,

2025

2024

2025

2024

Weighted average shares outstanding (Basic)

3536,~~786~~383,~~813~~277

28,~~364~~738,~~731~~307

35,~~217~~610,~~887~~619

2627,~~625~~335,~~955~~212

Additional dilutive shares

43,~~475~~673,~~951~~537

—3,607,365

4,~~672~~339,~~215~~322

—

Weighted average shares outstanding (Diluted)

40,~~262~~056,~~764~~814

2832,~~364~~345,~~731~~672

39,~~890~~949,~~102~~941

2627,~~625~~335,~~955~~212

The following potentially dilutive securities were excluded from the computation of earnings per share as of ~~June~~September 30, 2025 and 2024 because their effects would be anti-dilutive:

Three Months Ended June 30,

Six Months Ended June 30,

Three Months Ended September 30,

Nine Months Ended September 30,

2025

2024

2025

2024

Common stock warrants

—

3,~~627~~610,~~409~~743

—

3,627,409

Assumed conversion of preferred stock warrants

—

~~4,108,328~~—

—

4,108,328

Assumed conversion of preferred stock

—

~~1,454,509~~—

—

1,454,509

Assumed conversion of convertible notes

—

~~446~~237,~~563~~614

—

~~446~~237,~~563~~614

Stock options

23,~~796~~510,~~682~~565

61,~~132~~489,~~114~~310

23,~~796~~510,~~682~~565

6,~~132~~055,~~114~~728

Assumed conversion of ESPP

2242,~~057~~570

5135,~~291~~512

2242,~~057~~570

5135,~~291~~512

Total

23,~~818~~553,~~739~~135

155,~~820~~373,~~214~~179

23,~~818~~553,~~739~~135

15,~~820~~519,~~214~~100

(11) Income Taxes

The Company has recorded a provision for income taxes of $0.72 million for the ~~six~~nine months ended ~~June~~September 30, 2025. The effective tax rate of 5.1% differs from the United States statutory tax rate of 21% primarily due to state income tax, nondeductible stock compensation, research and development tax credits and the change in the valuation allowance. The Company had no provision for income taxes for the ~~six~~nine months ended ~~June~~September 30, 2024.

As discussed in “Note 16—Income Taxes” to the notes to the consolidated financial statements contained in the Annual Report, the Company has a valuation allowance against the full amount of its net deferred tax assets. The Company currently provides a valuation allowance against deferred tax assets when it is more likely than not that some portion or all of its deferred tax assets will not be realized. The Company has not recognized any unrecognized tax benefits in its balance sheet.

The Company is subject to income tax in the United States, as well as various state and international jurisdictions. The federal and state tax authorities can generally reduce a net operating loss (but not create taxable income) for a period outside the statute of limitations in order to determine the correct amount of net operating loss which may be allowed as a deduction against income for a period within the statute of limitations. Additional information regarding the statutes of limitations can be found in Note 16 - Income Taxes of the Company’s Annual Report.

The Inflation Reduction Act of 2022 included tax legislation that became effective in the first quarter of 2023. Significant legislation for corporate taxpayers includes a corporate alternative minimum tax of 15% for companies with $1 billion or more in average net financial statement profits over the three previous years, as well as a 1% indirect excise tax on the repurchase of shares by a publicly traded company. The Company does not expect this legislation to have an effect on the tax provision as of ~~June~~September 30, 2025, however the Company will continue to evaluate the effect on the tax provision each reporting period.

On July 4, 2025, President Trump signed into law the One Big Beautiful Bill (“OBBB”), which resulted in the extension of many provisions of the current tax law as well as other rule changes that could impact the Company’s tax provision in 2025 or 2026. Examples of the new tax law include the following:

•Full expensing of U.S. research and development costs under Section 174A.

•Retroactive expensing of unamortized U.S. research and development costs capitalized between 2022 and 2024; either all in 2025, or over two years in 2025 and 2026.

~~•Return of the Section 163(j) taxable income base excluding the deductions for depreciation and amortization in 2025 (change from “Tax EBIT” to “Tax EBITDA”).~~20

Table of Contents

•Return of the Section 163(j) taxable income base excluding the deductions for depreciation and amortization in 2025 (change from “Tax EBIT” to “Tax EBITDA”).

•Decrease in the Section 250 deduction for Net CFC Tested Income (formerly GILTI) to 40% (from 50%) in 2026, instead of the scheduled decrease to 37.5% prior to the OBBB.

•Decrease in the Section 250 deduction for foreign-derived income to 33.34% (from 37.5%) in 2026, instead of the scheduled decrease to 21.875% prior to the OBBB.

•Increase in the foreign tax credit rate on Net CFC Tested Income (formerly GILTI) to 90% (from 80%), and a 10% disallowance on repatriation, in 2026.

•Removal of the allocation of interest expense and research and development expense to Net CFC Tested Income (formerly GILTI) in calculating the foreign tax credit limitation, effective in 2026.

The Company isdecreased ~~currently~~its ~~evaluating~~current tax provision from $0.7 million for the ~~effect~~six months ending June 30, 2025 to $0.2 million for the nine months ending September 30, 2025 as a result of the OBBB onchanges ~~its~~related ~~future~~to ~~interim~~Section ~~and~~174A, ~~annual~~as ~~financial~~well ~~statements.~~as ~~The~~the ~~Company’s~~retroactive ~~deferred~~expensing ~~tax~~of ~~asset~~unamortized ~~for~~ U.S. research and development costs ~~may~~capitalized ~~reverse~~between in2022 ~~the~~and ~~subsequent~~2024. ~~financial~~As ~~statement,~~the ~~decreasing~~Company ~~taxes~~records ~~payable by~~ a ~~corresponding~~full ~~amount~~valuation oron ~~increasing~~deferred ~~other~~ tax ~~attributes~~assets, ~~for~~there ~~which~~is ano ~~valuation~~deferred ~~allowance~~tax isprovision recorded. ~~The~~as ~~full~~a ~~effect~~result of the OBBB ~~is not practical to estimate at this time~~.

(12) Commitments and Contingencies

medac Matter

In April 2021, the Company’s wholly owned subsidiary, Delcath Systems Ltd, issued to medac GmbH, a privately held, multi-national pharmaceutical company based in Germany (“medac”), an invoice for a €1 million milestone payment under a License, Supply and Marketing Agreement dated December 10, 2018 (the “medac Agreement”) between medac and the Company. The medac Agreement provided to medac the exclusive right to market and sell CHEMOSAT in certain designated countries for which the Company was entitled to a combination of upfront and success-based milestone payments as well as a fixed transfer price per unit of CHEMOSAT and specified royalties.

In response to medac’s subsequent dispute and non-payment of the invoice, on October 12, 2021, the Company notified medac in writing that it was terminating the medac Agreement due to medac’s nonpayment of the €1 million milestone payment, with the effective date of termination of the medac Agreement being April 12, 2022. On December 16, 2021, the Company initiated an arbitration proceeding pursuant to the dispute resolution procedures of the medac Agreement for the non-payment of the invoice.

On December 30, 2022, the parties reached a final settlement of the matter and the Company agreed to pay medac either (a) a royalty on sales of CHEMOSAT units over a defined minimum for a period of five years or until a maximum payment has been reached, or (b) a minimum annual payment of $0.2 million in the event the annual royalty payment does not reach the agreed minimum payment amount. The Company has estimated the remaining fair value of the settlement to be $0.8 million as of ~~June~~September 30, 2025 and recorded $0.6 million as other liabilities, non-current and $0.2 million as accrued expenses on the Company’s condensed consolidated balance sheet as of ~~June~~September 30, 2025.

Manufacturing and Supply Agreements

The Company has a License, Supply and Contract Manufacturing Agreement (as amended, the “Supply Agreement”) with Synerx Pharma, LLC and Mylan Teoranta for the supply of melphalan provided in the HEPZATO KIT. An amendment to the Supply Agreement was entered into on April 22, 2024, and effective as of May 1, 2024, which extends the term of the agreement through December 31, 2028, with an option to renew for successive five-year periods upon the mutual written consent of both parties. Although the Supply Agreement does not contain an annual minimum purchase quantity, the Agreement requires Delcath to order full lots of labeled melphalan vials. ~~The~~As of September 30, 2025, the Company ~~received~~has committed to purchase $2.15 million of melphalan under this Supply Agreement in ~~2025 which is recorded under accounts payable as of June 30, 2025~~2026.

Agreements Relating to Clinical Trial Support

The Company has engaged Precision for Medicine LLC (“PfM”) a Clinical Research Organization (“CRO”) to support the Company's Phase 2 clinical trials evaluating HEPZATO in combination with standard of care in patients with liver dominant mCRC and HER2-negative mBC. In addition to the CRO engagement, the Company has also contracted with other vendors, including those relating to data management as well as clinical trial sites as the studies progress. Deposits ~~totaling $2.3 million have been made by the Company in connection with these engagements that are to be applied to future payments due under the service agreements.~~

1921

Table of Contents

totaling $2.3 million have been made by the Company in connection with these engagements that are to be applied to future payments due under the service agreements.

(13) Fair Value Measurements

Contingent liabilities are re-measured to fair value each reporting period using projected financial targets, discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts are discounted back to the current period using a discounted cash flow model. Projected financial targets are based on our most recent internal operational budgets and may take into consideration alternate scenarios that could result in more or less profitability for the respective service line. Increases or decreases in projected financial targets and probabilities of payment may result in significant changes in the fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs in isolation may result in a significantly lower or higher fair value measurement.

The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The table below presents activity within Level 3 of the fair value hierarchy, our liabilities carried at fair value relating to the medac settlement, for the nine months ended September 30, 2025:

	Level 3
(In thousands)	Contingentliabilities
Balance at January 1, 2025	$	974
Change due to liability payment	(208)
Liability fair value adjustment	(5659)
Total change in foreign exchange	92101
Balance at June 30, 2025	$	802
Balance at September 30, 2025	$	808

The following tables present information about the Company’s financial assets and liabilities that have been measured at fair value as of ~~June~~September 30, 2025 and December 31, 2024 and indicate the fair value hierarchy of the valuation inputs utilized to determine such fair value.

	June 30, 2025
	September 30, 2025
(In thousands)	Quoted Prices inActive Markets(Level 1)		SignificantOtherObservableInputs(Level 2)		SignificantUnobservableInputs(Level 3)		Total
Assets:
Money market funds	$	85	$	—	$	—	$	85
U.S. government agency bonds	—		4647,~~584~~099		—		4647,~~584~~099
Total Assets	$	85	$	4647,~~584~~099	$	—	$	4647,~~592~~104
Liabilities:
Contingent Liability	$	—	$	—	$	~~802~~808	$	~~802~~808
Total Liabilities	$	—	$	—	$	~~802~~808	$	~~802~~808

2022

Table of Contents


	December 31, 2024
(In thousands)	Quoted Prices in Active Markets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total
Assets:
Money market funds	$	9	$	—	$	—	$	9
U.S. government agency bonds	—		20,821		—		20,821
Total Assets	$	9	$	20,821	$	—	$	20,830

Liabilities:
Contingent Liability	$	—	$	—	$	974	$	974
Total Liabilities	$	—	$	—	$	974	$	974

(14) Segment Information

The Company operates its business primarily in the United States and Europe on a consolidated basis in one reportable segment - the research, development, manufacture and distribution of hepatic delivery systems for the use in the treatment of specific conditions (the “reportable segment”). The Company’s chief operating decision maker (“CODM”) is comprised of a single management team consisting of the Chief Financial Officer, Chief Operating Officer, Chief Medical Officer and General Manager that reports to the Chief Executive Officer. The CODM uses consolidated gross profit and net income or loss, which can be found on the Consolidated Statements of Operations and Comprehensive Loss, to assess financial performance. These financial metrics are used to monitor budget versus actual results. See Note 2 for a description of the Company’s disaggregated revenue by product line. Significant segment expenses reviewed by the CODM are presented in the Company’s Consolidated Statements of Operations and Comprehensive Loss. The measure of segment assets provided to the chief operating decision maker is reported on the balance sheet as total consolidated assets.

(15) Subsequent Events

The Company has evaluated subsequent events for adjustment to or disclosure in these condensed consolidated financial statements through the date of this report and has not identified any recordable or disclosable events not otherwise reported in these financial statements or the notes thereto.

2123

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the financial condition and results of operations of Delcath Systems, Inc. (“Delcath” or the “Company”) should be read in conjunction with the unaudited interim condensed consolidated financial statements and notes thereto contained in Item 1 of Part I of this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (the “Annual Report”), which was filed with the Securities and Exchange Commission (the “SEC”) on March 6, 2025, to provide an understanding of its results of operations, financial condition and cash flows.

All references in this Quarterly Report on Form 10-Q to “we,” “our,” “us” and the “Company” refer to Delcath Systems, Inc., and its subsidiaries unless the context indicates otherwise.

This Quarterly Report on Form 10-Q and may include trademarks, service marks and trade names owned or licensed by us, including CHEMOFUSE, CHEMOSAT, CHEMOSATURATION, DELCATH, HEPZATO, HEPZATO KIT, PHP and THE DELCATH PHP SYSTEM. Solely for convenience and readability, trademarks, service marks and trade names, including logos, artwork and other visual displays, may appear in a non-traditional trademark usage manner, including without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of the Company or the Company’s licensor, as applicable.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 with respect to our business, financial condition, liquidity, and results of operations. Words such as “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” and the negative of these terms or other comparable terminology often identify forward-looking statements. Statements in this Quarterly Report on Form 10-Q that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”). These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements, including the risks discussed in Item 3 “Quantitative and Qualitative Disclosures About Market Risk,” and the risks discussed in Part II, Item 1A under “Risk Factors” and the risks detailed from time to time in our future reports filed with the SEC. These forward-looking statements include, but are not limited to, statements about:

•our estimates regarding sufficiency of our cash resources, anticipated capital requirements, future revenue and our need for additional financing;

•the commencement of future clinical trials, if any, and the results and timing of those clinical trials;

•our expectations and timing related to our Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic colorectal cancer;

•our expectations and timing related to our Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for liver-dominant metastatic breast cancer;

•our expectations that the publication of additional data from our Phase 3 FOCUS Trial, or any other trial that we initiate in the future, will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States;

•our ability to successfully commercialize CHEMOSAT, HEPZATO KIT, and future products, if any, generate revenue and successfully obtain reimbursement for the products and/or the associated procedures;

•our sales, marketing and distribution capabilities and strategies, including for the commercialization and manufacturing of CHEMOSAT, HEPZATO KIT, and future products, if any;

•the rate and degree of market acceptance and clinical utility of CHEMOSAT, HEPZATO KIT, and future products, if any;

2224

Table of Contents

•developments relating to our competitors and our industry;

•the initiation and success of our research and development programs;

•submission and timing of applications for regulatory approval and approval thereof;

•our ability to successfully source components of CHEMOSAT, HEPZATO KIT, and future products, if any, and enter into supplier contracts;

•our ability to source melphalan and other critical components necessary to manufacture HEPZATO KIT;

•our ability to successfully manufacture CHEMOSAT and HEPZATO KIT;

•our ability to comply with applicable requirements, including those associated with the Company’s execution of the National Drug Rebate Agreement;

•our ability to successfully negotiate and enter into agreements with distribution, strategic and corporate partners;

•our estimates of potential market opportunities and our ability to successfully realize these opportunities; and

•contributions to adjusted EBITDA.

Many of the important factors that will determine these results are beyond our ability to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. Except as otherwise required by law, we do not assume any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

Company Overview

We are an interventional oncology company focused on the treatment of cancers primary or metastatic to the liver. Our lead product, the HEPZATO KIT (melphalan for Injection/Hepatic Delivery System), a drug/device combination product (“HEPZATO” or “HEPZATO KIT”), was approved by the US Food and Drug Administration (the “FDA”) on August 14, 2023, indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection, or radiation. The first commercial use of the HEPZATO KIT for the treatment of metastatic hepatic dominant uveal melanoma (“mUM”) took place in January 2024.

In the United States, HEPZATO is considered a combination drug and device product and is regulated as a drug by the FDA. Primary jurisdiction for regulation of HEPZATO has been assigned to the FDA’s Center for Drug Evaluation and Research. The FDA has granted us six orphan drug designations (five for melphalan in the treatment of patients with ocular (uveal) melanoma, cutaneous melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and neuroendocrine tumor indications and one for doxorubicin in the treatment of patients with hepatocellular carcinoma).

We have sufficient raw material and component constituent parts of the HEPZATO KIT to meet anticipated demand and we intend to manage supply chain risk through stockpiled inventory and contracting with multiple suppliers for critical components.

In Europe, the hepatic delivery system is a stand-alone medical device having the same device components as HEPZATO, but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used at major medical centers to treat a wide range of cancers in the liver. On February 28, 2022, CHEMOSAT received Medical Device Regulation (“MDR”) certification under the European Medical Devices Regulation (EU)2017/745, which may be considered by jurisdictions when evaluating reimbursement. As of March 1, 2022, we have assumed direct responsibility for sales, marketing and distribution of CHEMOSAT in Europe.

~~Our~~On ~~clinical~~October ~~development~~18, ~~program~~2025, ~~for~~we ~~HEPZATO~~announced ~~was~~the ~~comprised~~results of the ~~FOCUS~~investigator-initiated ~~Clinical~~CHOPIN ~~Trial~~clinical ~~for~~trial. ~~Patients~~The ~~with~~randomized ~~metastatic~~Phase ~~hepatic~~2 ~~dominant~~trial ~~Uveal~~was ~~Melanoma~~designed (to compare the ~~“FOCUS~~safety, ~~Trial”)~~tolerability, aand ~~global~~efficacy ~~registration~~of ~~clinical~~CHEMOSAT ~~trial~~with ~~that~~melphalan ~~investigated~~for ~~objective~~percutaneous ~~response~~hepatic ~~rate~~perfusion in(PHP) ~~patients~~when ~~with~~used ~~mUM.~~alone ~~The~~versus ~~current~~when ~~focus~~combined ofwith ~~our~~the ~~clinical~~systemic ~~development~~immune ~~program~~checkpoint isinhibitors to(ICI) ~~generate~~ipilimumab ~~clinical~~and ~~data~~nivolumab. ~~for~~Ipilimumab ~~CHEMOSAT~~ and ~~HEPZATO~~nivolumab inare ~~patients~~approved ~~with~~by ~~mUM,~~the ~~either~~FDA asand ~~monotherapy~~European orUnion infor ~~combination~~the ~~with~~treatment ~~immunotherapy.~~of Onunresectable ~~May~~metastatic 6,melanoma. ~~2024,~~The weCHOPIN ~~announced~~trial ~~the~~included ~~publication~~76 ofpatients ~~results~~randomized ~~from~~1:1 ~~our~~to ~~Phase~~receive 3two ~~FOCUS~~PHP ~~Trial,~~treatments ~~including~~alone anat ~~Overall~~weeks ~~Response~~one ~~Rate~~and seven (~~“ORR”~~PHP group) ofor ~~36.35,~~four ~~which~~cycles ~~included 7.7%~~ of ~~patients~~ICI ~~with~~every ~~Complete~~three ~~Response,~~weeks asover ~~determined~~approximately bynine anweeks ~~Independent~~with ~~Review~~two ~~Committee.~~PHP Antreatments ~~ORR~~at ofweeks ~~36.3%~~one inand ~~the~~seven ~~FOCUS~~(combination ~~study~~group). ~~was~~The ~~statistically~~primary ~~significantly~~study ~~better~~endpoint ~~than~~of ~~the~~one-year ~~pooled~~progression-free ~~ORR~~survival ~~estimate~~rate (awas ~~weighted~~met ~~mean~~with of54.7% in the ~~observed~~combination ~~ORR)~~group ofversus 515.58% in the ~~historical~~PHP ~~control~~ group. WeThe ~~expect~~secondary ~~that~~endpoints ~~the~~included ~~publication~~Safety, ~~will~~Overall ~~support~~Survival ~~increased~~(“OS”), ~~clinical~~Progression ~~adoption~~Free ofSurvival (“PFS”) and ~~reimbursement~~Overall ~~for~~Response ~~CHEMOSAT~~Rate in(“ORR”). ~~Europe,~~The ~~and~~combination ~~support~~group ~~reimbursement~~saw inan ~~various~~increase ~~jurisdictions,~~in ~~including~~median ~~the~~OS ~~United~~of ~~States.~~

2325

Table of Contents

23.1 months versus 19.6 months (HR = 0.39; p = 0.006), median PFS 12.8 months versus 8.3 months (HR = 0.34; p<0.001) and ORR of 76.3% in the combination group versus 39.5% (p<0.001). Grade 3 or higher treatment-related adverse events were more frequent in the combination group (81.6% versus 40.5%, P<0.001), but most were manageable with standard care. Overall, the combination treatment was well tolerated, with types, rates and frequencies of adverse events consistent with individual use of PHP and checkpoint inhibitors. No new safety signals were identified.

Our clinical development program for HEPZATO was comprised of the FOCUS Clinical Trial for Patients with metastatic hepatic dominant Uveal Melanoma (the “FOCUS Trial”), a global registration clinical trial that investigated objective response rate in patients with mUM. The current focus of our clinical development program is to generate clinical data for CHEMOSAT and HEPZATO in patients with mUM, either as monotherapy or in combination with immunotherapy. On May 6, 2024, we announced the publication of results from our Phase 3 FOCUS Trial, including an ORR of 36.35, which included 7.7% of patients with Complete Response, as determined by an Independent Review Committee. An ORR of 36.3% in the FOCUS study was statistically significantly better than the pooled ORR estimate (a weighted mean of the observed ORR) of 5.5% in the historical control group. We expect that the publication will support increased clinical adoption of and reimbursement for CHEMOSAT in Europe, and support reimbursement in various jurisdictions, including the United States.

In addition to HEPZATO’s use to treat mUM, the Company believes that HEPZATO has the potential to treat other cancers in the liver, such as metastatic colorectal cancer, metastatic breast cancer, metastatic neuroendocrine tumors and intrahepatic cholangiocarcinoma.

Our IND application for a Phase 2 clinical trial evaluating HEPZATO in combination with SOC for liver-dominant mCRC was cleared by the FDA in December 2024. The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with trifluridine-tipiracil and bevacizumab compared to trifluridine-tipiracil and bevacizumab alone in patients with liver-dominant mCRC receiving third-line treatment. Approximately 90 patients will be enrolled in this randomized, controlled trial. ~~The~~Patient enrollment began during the third quarter of 2025, with the study ~~will~~expected to take place at more than 20 sites across the United States and Europe. In July 2025, ~~with~~we ~~patient~~received ~~enrollment~~authorization ~~expected~~from tothe ~~begin~~European inUnion and United Kingdom regulatory authorities for the ~~second~~clinical ~~half~~study of ~~2025~~Melphalan for Injection/Hepatic Delivery System in patients with refractory metastatic colorectal cancer with the liver dominant disease. The trial’s primary endpoint, hepatic progression-free survival (“hPFS”), is anticipated to read out by the end of 2027, while overall survival (“OS”), a secondary endpoint, is expected in 2028. We estimate that the total addressable market (“TAM”) for liver-dominant mCRC receiving third-line treatment is between 6,000 and 10,000 patients annually in the United States. This market includes patients who present with significant liver disease burden, with liver-dominant status determined through radiological and clinical criteria. By targeting this patient population, we aim to provide a novel treatment option for those with limited therapeutic alternatives.

On April 28, 2025, we announced our IND application clearance by the FDA for the Phase 2 clinical trial of HEPZATO in liver-dominant metastatic breast cancer (“mBC”). The Phase 2 trial will evaluate the safety and efficacy of HEPZATO in combination with SOC versus SOC alone in patients with liver-dominant HER2-negative mBC following the failure of previous treatments. The SOC options will be the physician’s choice of eribulin, vinorelbine or capecitabine. We expect approximately 90 patients will be enrolled in this randomized, controlled trial. The study will take place at more than 20 sites across the United States and Europe, with patient enrollment expected to begin in the ~~fourth~~first quarter of ~~2025~~2026. The trial’s primary endpoint, hPFS, is anticipated to read out by the end of 2028, while results for OS, a secondary endpoint, is expected in 2029.

We estimate that approximately 7,000 patients annually in the United States are affected by HER2-negative metastatic breast cancer with liver metastases and are candidates for third line treatment. This population includes patients with a significant burden of liver metastases, which are likely to be the primary cause of mortality. By focusing on this demographic, we intend to offer a novel therapeutic option to those patients with limited treatment alternatives.

We believe that these and similar disease states are areas of unmet medical needs that represent significant market opportunities.

We expense research and development costs as they are incurred. We expect our research and development expenses to increase for the foreseeable future relating to the costs required to complete these Phase 2 clinical trials.

Our expected research and development expenses will consist primarily of:

•salaries and related overhead expenses for personnel in research and development functions, including stock-based compensation;

•fees paid to trial sites, consultants, and the contract research organization (CRO) for the clinical trials, along with other related clinical trial fees, including, but not limited to, clinical trial database management, clinical trial material management and statistical compilation and analysis; and

•costs related to compliance with regulatory requirements.

At this time, we cannot reasonably estimate or know the exact nature, timing and estimated costs of the efforts that will be necessary. Non-refundable advance payments that are made for future research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the services are performed, or when it is no longer expected that the services will be rendered.26

Table of Contents

Results of Operations

Three months ended June 30,

Six months ended June 30,

Three months ended September 30,

Nine months ended September 30,

(In thousands)

2025

2024

2025

2024

Total revenues

2420,~~156~~563

711,~~766~~200

4364,~~940~~503

1022,~~905~~105

Cost of goods sold

(32,~~318~~624)

(1,~~519~~640)

(68,~~163~~787)

(24,~~422~~062)

Gross profit

2017,~~838~~939

69,~~247~~560

3755,~~777~~716

818,~~483~~043

Research and development expenses

67,~~882~~986

3,~~394~~866

1119,~~889~~875

710,~~094~~960

Selling, general and administrative expenses

1110,~~366~~341

6,~~765~~953

2232,~~656~~997

1522,~~579~~532

Total operating expenses

18,~~248~~327

10,~~159~~819

3452,~~545~~872

2233,~~673~~492

Operating income (loss)

~~2,590~~(388)

(31,~~912~~259)

32,~~232~~844

(1415,~~190~~449)

Interest and other income (expense)

~~615~~763

(93,~~829)~~123

12,~~237~~000

(107,~~662~~539)

Income tax expense

508

—

703

—

Income tax (benefit) expense

(455)

—

248

—

Net income (loss)

~~2,697~~830

~~(13~~1,~~741)~~864

34,~~766~~596

(2422,~~852~~988)

Revenue

The increase in total revenue for the three and ~~six~~nine months ended ~~June~~September 30, 2025 compared to the same periods in 2024 was due to the continued commercial expansion and demand of HEPZATO in the United States and CHEMOSAT in Europe. In the ~~six~~nine months ended ~~June~~September 30, 2025, 2022 facilities had treated at least one patient with HEPZATO versus 711 facilities in the ~~six~~nine months ended ~~June~~September 30, 2024.

Cost of Goods Sold

The change in cost of goods sold for the three and ~~six~~nine months ended ~~June~~September 30, 2025 compared to the same periods in 2024 is directly related to changes in demand for product revenue.

Research and Development Expenses

Research and development expenses are incurred for the development of HEPZATO and consist primarily of payroll and payments to contract research and development companies. The increase for the three and ~~six~~nine months ended ~~June~~September 30, 2025 compared to the same period in 2024 is due to costs associated with expanding the clinical team including the share-based compensation expense related to an increase in headcount and initiation of the Phase 2 clinical trial evaluating HEPZATO in combination with standard of care for mCRC and mBC. In 2024, these costs primarily related to medical affairs and regulatory costs associated with the approved products.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of payroll, rent and professional services such as accounting, legal, marketing and commercial preparation services. For the three and ~~six~~nine months ended ~~June~~September 30, 2025 compared to the same periods in 2024, selling, general and administrative expenses increased due to continued commercial expansion activities including marketing-related travel expenses and additional personnel on the commercial team. In addition, the increase in personnel along with higher grant date exercise prices has increased the share-based compensation expense.

Interest and other Income/Expense

Interest and other income in 2025 is primarily related to the interest income associated with marketable securities and cash on hand. In 2024, this amount was offset by interest expense related to our debt instruments and the change in fair value of warrant liability. There was no interest expense for the three and ~~six~~nine months ended ~~June~~September 30, 2025 due to all debt being paid off in ~~2024. There was no change in warrant valuation during the three and six months ended June 30, 2025 due to the exercise of all Tranche B Warrants in 2024.~~

~~Liquidity and Capital Resources~~27

At June 30, 2025, we had cash and cash equivalents totaling $34.4 million and short-term investments totaling $46.6 million, as compared to cash, cash equivalents and restricted cash totaling $32.4 million and short-term investments totaling $20.8 million at December 31, 2024. During the six months ended June 30, 2025, $9.5 million of cash was provided by operating activities

Table of Contents

~~compared to $14~~2024.~~0 million~~ ~~used~~There inwas ~~operating activities during the six months ended June 30, 2024,~~ no ~~principal~~change ~~payments~~in ~~were~~warrant ~~made~~valuation during the ~~six~~three and nine months ended ~~June~~September 30, 2025, ~~compared~~due to ~~$6.1 million for principal payments during~~ the ~~six~~exercise ~~months~~of ~~ended~~all ~~June~~Tranche ~~30,~~B ~~2024.~~Warrants Atin ~~June 30,~~ 2024~~, we had cash, cash equivalents and restricted cash totaling $14~~.~~8 million.~~

Liquidity and Capital Resources

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:


	Nine months ended September 30,
	2025		2024
Net cash provided by (used in) operating activities	14,268		(17,675)
Net cash (used in) provided by investing activities	(26,029)		14,247
Net cash provided by (used in) financing activities	20,992		(975)
Foreign currency effects on cash	170		22
	$	9,401	$	(4,381)

At September 30, 2025, we had cash and cash equivalents totaling $41.8 million and short-term investments totaling $47.1 million, as compared to cash and cash equivalents totaling $8.3 million and short-term investments totaling $5.7 million at September 30, 2024.

We believe that our current cash on hand, cash equivalents and investments will be sufficient to support our current operations through at least 12 months from the issuance of these consolidated financial statements. Our actual future liquidity and capital requirements will depend on numerous factors, including the initiation and progress of clinical trials and research and product development programs; obtaining regulatory approvals and complying with applicable laws and regulations; the timing and effectiveness of product commercialization activities, including marketing arrangements; the timing and costs involved in preparing, filing, prosecuting, defending and enforcing intellectual property rights; the resolution of any disputes with third parties; and the effect of competing technological and market developments.

Capital Commitments

Our capital commitments over the next twelve months include (a) $108.40 million to satisfy accounts payable, accrued expenses, current lease liabilities and current medac settlement. Additional capital commitments beyond the next twelve months include (a) $1.21 million of lease liabilities and (b) $0.6 million for settlement of litigation with medac.

Sources of Liquidity

June 2024 Shelf Registration Statement

On June 28, 2024, we filed a universal shelf registration statement on Form S-3 (the “June 2024 Shelf Registration Statement”) with the SEC, pursuant to which we may offer, issue and sell any combination of shares of our common stock, par value $0.01 per share, shares of our preferred stock, par value $0.01 per share, debt securities, warrants to purchase common stock, preferred stock and/or debt securities, in one or more series, and units consisting of any combination of the other types of securities registered under such June 2024 Shelf Registration Statement in an aggregate amount of up to $150 million, in each case, to the public in one or more registered offerings.

Series F Warrants

In May 2020, we completed an underwritten public offering consisting of shares of common stock, Series F warrants to purchase shares of common stock and, to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase shares of common stock. The Series F Warrants had an exercise price of $10.00 per share of common stock and expired on May 5, 2025, while the pre-funded warrants issued in such offering have an exercise price of $0.01, if exercised via cash payment. 1,615,775 Series F Warrants were exercised during the ~~six~~nine months ended ~~June~~September 30, 2025.

Critical Accounting Estimates

~~There~~Management has completed its quarterly evaluation of estimates and there have been no material changes to the process of our critical accounting estimates as they were reported in our Annual Report on Form 10-K filed with the SEC on March 6, 2025.

Table of Contents

Application of Critical Accounting Policies

Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America. There were no material changes to our critical accounting policies as reported in our Annual Report. A description of certain accounting policies that may have a significant impact on amounts reported in the financial statements is disclosed in “Note 3 – Summary of Accounting Policies” to the notes to the consolidated financial statements contained in the Annual Report.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its Certifying Officers), evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of September 30, 2025, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

Table of Contents

15d-15(e) under the Exchange Act. Based on the evaluation as of June 30, 2025, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the ~~six~~nine months ended ~~June~~September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2729

Table of Contents

PART II: OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, claims are made against the Company in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties, or injunctions prohibiting us from selling our products or engaging in other activities.

medac Matter

See Note 12 - “Commitment and Contingencies - medac Matter” for more information.

Item 1A. Risk Factors

Our business is subject to various risks and uncertainties that may have a material adverse effect on our business, financial condition or results of operations. You should carefully consider the risks and uncertainties described in the Annual Report on Form 10-K filed on March 6, 2025. Our business faces significant risks and uncertainties, and those described in our Annual Report may not be the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also significantly impair our business, financial condition or results of operations. If any of these risks or uncertainties occur, our business, financial condition or results of operations could suffer, the market price of our common stock could decline and you could lose all or part of your investment in our common stock.

The information presented below updates, and should be read in conjunction with, the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Other than the risk factors set forth below, we believe there have been no material changes in our risk factors from those disclosed in the Annual Report.

If we fail to comply with reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

We participate in governmental programs that impose extensive drug price reporting and payment obligations on pharmaceutical manufacturers. Medicaid is a joint federal and state program that is administered by the states for low income and disabled beneficiaries. Under the Medicaid Drug Rebate Program (the “MDRP”), as a condition of federal funds being made available for our covered outpatient drugs under Medicaid, we pay a rebate to state Medicaid programs for each unit of our covered outpatient drugs dispensed to a Medicaid beneficiary and paid for by the state Medicaid program. Medicaid rebates are based on pricing data that we report on a monthly and quarterly basis to the Centers for Medicare & Medicaid Services (“CMS”), the federal agency that administers the MDRP and Medicare programs. For the MDRP, the data includes the Average Manufacturer Price (“AMP”) for each drug and, in the case of innovator products, best price. In connection with Medicare Part B, we will continue to submit to CMS the average sales price (“ASP”) on a quarterly basis. ASP is calculated based on a statutorily defined formula, as well as regulations and interpretations of the statute by CMS. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. If we fail to provide information on a timely basis or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, in which case payment would not be available for our covered outpatient drugs.

Federal law requires that any company that participates in the MDRP also participate in the 340B program. The 340B program is administered by Health Resources & Services Administration (“HRSA”) and requires us, as a participating manufacturer, to agree to charge statutorily defined covered entities no more than the 340B “ceiling price” for our covered outpatient drugs when used in an outpatient setting. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low income patients. A drug that is designated for a rare disease or condition by the Secretary of Health and Human Services is not subject to the 340B ceiling price requirement if the sale is to one of the following types of covered entities: rural referral centers, sole community hospitals, critical access hospitals, and free standing cancer hospitals. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered outpatient drug as calculated under the MDRP. We must report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B eligible drugs. HRSA has also finalized a revised administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs.

2830

Table of Contents

In order to be eligible to have drug products paid for with federal funds under Medicaid and Medicare Part B and purchased by certain federal agencies and grantees, we must also participate in the VA/FSS pricing program. Under the VA/FSS program, we must report the Non-FAMP for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We must also pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties.

Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for certain drugs, and states may impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business.

Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts, which can change and evolve over time. Such pricing calculations and reporting, along with any necessary restatements and recalculations, could increase our costs for complying with the laws and regulations governing the MDRP and other governmental programs, and under the MDRP could result in an overage or undercharge in Medicaid rebate liability for past quarters. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price.

We cannot assure that our submissions will not be found to be incomplete or incorrect.

Changes in healthcare law and implementing regulations, including government restrictions on pricing and reimbursement, as well as healthcare policy and other healthcare payor cost-containment initiatives, may have a material adverse effect on us

In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system and efforts to control healthcare costs, including drug prices, that could have a significant negative impact on our business, including preventing, limiting or delaying regulatory approval of our drug candidates and reducing the sales and profits derived from our products once they are approved. For example, on July 4, 2025, the annual reconciliation bill, the “One Big Beautiful Bill” (“OBBB”) was signed into law which, is expected to reduce Medicaid spending and enrollment by implementing work requirements for some beneficiaries, capping state-directed payments, reducing federal funding, and limiting provider taxes used to fund the program. OBBB also narrows access to ACA marketplace exchange enrollment and declines to extend the ACA enhanced advanced premium tax credits, set to expire in 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance.

On August 16, 2022, the IRA was signed into law. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (and the maximum price as a result of the negotiations becoming effective beginning on January 1, 2026), with prices that can be negotiated subject to a cap (the “Medicare Drug Price Negotiation Program”); imposes rebates under Medicare Part B and Medicare Part D for price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.

These provisions took effect progressively starting in fiscal year 2023. On August 15, 2024, HHS announced the agreed-upon prices of the first ten drugs that were to be subject to price negotiations, which take effect in January 2026. Each year thereafter more Part B and Part D products will become subject to the Medicare Drug Price Negotiation Program, although the Medicare Drug Price Negotiation Program is currently subject to legal challenges. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year. In response to an October 2022 executive order, on February 14, 2023, HHS released a report outlining three new models for

2931

Table of Contents

testing by the CMS Innovation Center which will be evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act was announced. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.

Further, the current Trump administration is pursuing policies to reduce regulations and expenditures across government including at the HHS, the FDA, CMS and related agencies. These actions, presently directed by executive orders or memoranda from the Office of Management and Budget, may propose policy changes that create additional uncertainty for our business. These actions and proposals include, for example, (1) reducing agency workforce, program cuts; (2) rescinding a Biden administration executive order tasking the Center for Medicare and Medicaid Innovation (CMMI) to consider new payment and healthcare models to limit drug spending; (3) eliminating the Biden administration’s executive order that directed HHS to establish an AI task force and to develop a strategic plan; (4) directing HHS and other agencies to lower prescription drug costs through a variety of initiatives, including by improving upon the Medicare Drug Price Negotiation Program and establishing Most-Favored-Nation pricing for pharmaceutical products; (5) imposing tariffs of imported pharmaceutical products; and (6) directing certain federal agencies to enforce existing law regarding hospital and price plan transparency and by standardizing prices across hospitals and health plans. Additionally, in its June 2024 decision in Loper Bright Enterprises v. Raimondo (Loper Bright), the U.S. Supreme Court overturned the longstanding Chevron doctrine, under which courts were required to give deference to regulatory agencies’ reasonable interpretations of ambiguous federal statutes. The Loper Bright decision could result in additional legal challenges to current regulations and guidance issued by federal agencies applicable to our operations, including those issued by the FDA. Congress may introduce and ultimately pass health care related legislation that could, among others, impact the drug approval process and modify the Medicare Drug Price Negotiation Program created under the IRA and expand the orphan drug exclusion in the IRA. We cannot predict which additional measures may be adopted or the impact of current and additional measures on the marketing, pricing and demand for our products, if approved, which could have a material adverse effect on our business, financial condition and results of operations.

Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.

New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. The Tax Cuts and Jobs Act, the Coronavirus Aid, Relief, and Economic Security Act and the IRA enacted many significant changes to the United States tax laws. For example, effective January 1, 2022, the Tax Cuts and Jobs Act eliminated the option to deduct research and development expenses for tax purposes in the year incurred and required taxpayers to capitalize and subsequently amortize such expenses over five years for research activities conducted in the United States and over 15 years for research activities conducted outside the United States. The OBBB restored the tax deductibility of research and development expenses in the year incurred for research activities conducted in the United States for tax years beginning after December 31, 2024. We are evaluating the potential impact that this and other changes under the OBBB may have on our business. Future guidance from the Internal Revenue Service and other tax authorities with respect to any legislation may affect us, and certain aspects of such legislation could be repealed or modified in future legislation or sunset in future years. In addition, it is uncertain if and to what extent various states will conform to federal tax laws. Future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future tax expense.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

3032

Table of Contents

Item 5. Other Information

Rule 10b5-1 Trading Plans

During the three months ended ~~June~~September 30, 2025, no Section 16 officers and directors adopted, modified or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act).

There were no “non-Rule 10b5-1 trading arrangements” as defined in Item 408 of Regulation S-K of the Exchange Act adopted, modified or terminated during the three months ended ~~June~~September 30, 2025 by our Section 16 officers or directors.

3133

Table of Contents

Item 6. Exhibits
ExhibitNo.						Description
3.1						Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1/A filed September 25, 2019).
3.2						Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October 17, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on October 23, 2019).
3.3						Certificate of Correction to Amendment to the Amended and Restated Certificate of Incorporation of the Company dated October 22, 2019 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on October 23, 2019).
3.4						Amendment to the Amended and Restated Certificate of Incorporation of the Company, effective December 24, 2019 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 30, 2019).
3.5						Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated November 23, 2020 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on November 24, 2020).
3.6						Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, dated June 12, 2023 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 13, 2023).
3.7						Certificate of Designation of Preference, Rights and Limitations of the Series F Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K on March 30, 2023).
3.8						Amended and Restated By-Laws of the Company. (incorporated by reference to Exhibit 3.81 to the Company’s Quarterly Report on Form 108-QK filed on August 515, ~~2024~~2025).
10.1*						Delcath Systems Inc. 2020 Omnibus Equity Incentive Plan, as amended.
10.2*						Delcath Systems, Inc. 2021 Employee Stock Purchase Plan, as amended.
10.3*						2023 Inducement Plan, as amended.
31.1*						Certification by Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
31.2*						Certification by Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*
32.1*+						Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.**
32.2*+						Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.**
101.INS						XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH						Inline XBRL Taxonomy Extension Schema Document
101.CAL						Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE						Inline XBRL Taxonomy Extension Presentation Linkbase Document
104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

*Filed herewith.

Table of Contents

+ This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act whether made before or after the date hereof and irrespective of any general incorporation language in any filing, except to the extent the Company specifically incorporates it by reference.

3334

Table of Contents

DELCATH SYSTEMS, INC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			DELCATH SYSTEMS, INC.
August 6, 2025			/s/ Gerard Michel
November 4, 2025			/s/ Gerard Michel
			Gerard Michel
			Chief Executive Officer(Principal Executive Officer)
August 6, 2025			/s/ Sandra Pennell
November 4, 2025			/s/ Sandra Pennell
			Sandra Pennell
			Chief Financial Officer(Principal Financial and Accounting Officer)

3435

Filing Compare · DELCATH SYSTEMS, INC.